Cat#:RP-3145H;Product Name:Recombinant Human Coagulation Factor VIII / F8 Protein;Synonym:AHF; F8B; DXS1253E,Factor 8; F8C; HEMA; FVIII; ;Background:Gene ID: 2157. F8, the full name is coagulation factor VIII, also known as AHF; F8B; F8C; HEMA; FVIII; DXS1253E. Factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. The F8 gene is conserved in chimpanzee, Rhesus monkey, dog, cow, mouse, and rat. Factor VIII (FVIII) is a key component of the fluid phase of the blood coagulation system. Human factor VIII is a single chain of about 300kDa consisting of domains described as A1-A2-B-A3-C1-C2. The role of factor VIII is to increase the catalytic efficiency of factor IXa in the activation of factor X. Variants of these factors lead frequently also to severe bleeding disorders.;Description:Factor 8 / F8 Protein expressed in CHO is a glycosylated polypeptide chain having a 1438aa (170kd) and consisting of two dimer chains 80 kD and 90 kD. The Factor VIII lacks central region of B-domain region. The recombinant human F8 protein is purified using our unique purification methods.;Source:CHO cells;Purity:Greater than 97.0% as determined by SDS-PAGE.;Bioactivity:The specific activity of Factor VIII protein was found to be 7,058 IU/mg.;Formulation:Each IU F8 human was lyophilized from a solution containing 30ug PEG, 1.6ng VWF, 4ug calcium, and 0.25mg HSA.;Stability:Recombinant human F8 Protein is stable for up to 1 year from date of receipt at -70℃;Reconstitution:It is recommended to reconstitute 250IU lyophilized Factor VIII / F8 protein in 5ml sterile 18M-cm H2O, which can then be further diluted to other aqueous solutions.;Host Species:Human;Storage:Lyophilized Factor VIII / F8 human although stable at room temperature for 3 weeks, should be stored at -20 or -70℃. Upon reconstitution Factor-VIIIhuman should be stored at 4°C between 2-7 days and for future use below -20°C. Please avoid freeze-thaw cycles.;Usage:For Research Use Only!;References:Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Lai J, et al. Blood, 2017 Jun 15.;